Lancet:多途径共同干预可预防老年痴呆(FINGER研究)

2015-03-14 姜英浩 MedSci原创

在既往的多项观察性研究中,都报道了痴呆的风险与多种血管或其他生活方式相关的风险因素有密切的联系。在芬兰老年健康、预防认知损伤研究(FINGER)中,研究人员为了验证概念,进行了一项随机对照试验,试图评估一种多途径的方法预防大众中高风险老年人群的认知损伤。该结果在线发表于2015年3月13日的The Lancet杂志上。 该试验时一项双盲的随机对照试验,研究人员募集了60-77岁的老年人,这些人均

在既往的多项观察性研究中,都报道了痴呆的风险与多种血管或其他生活方式相关的风险因素有密切的联系。在芬兰老年健康、预防认知损伤研究(FINGER)中,研究人员为了验证概念,进行了一项随机对照试验,试图评估一种多途径的方法预防大众中高风险老年人群的认知损伤。该结果在线发表于2015年3月13日的The Lancet杂志上。

该试验时一项双盲的随机对照试验,研究人员募集了60-77岁的老年人,这些人均参加过曾经进行的全国性调查。选入标准参考CAIDE(心血管风险、年龄、痴呆),痴呆风险分数至少6分,认知水平较该年龄平均水平持平或略低。将这些受试者按1:1随机分配至干预组和对照组:干预组进行2年的多途径干预(饮食、运动、认知训练、血管风险监控);对照组给予普通的健康护理。采用区组随机方法,区块为4,通过电脑分配完成。主要评估指标为通过全面的神经心理测验(NTB)z分数测量得认知水平变化。采用改良的意向治疗分析(所有至少接受过1个后基线观测的受试者)。

结果表明,从2009年9月7日至2011年11月24日,共2654名受试者参与了此研究,1260名参与了随机分组。其中干预组631人,对照组629人。干预组591人(94 %)与对照组599人(95 %)接受了至少一次后基线评估,作为改良的意向治疗分析(mITT)。干预组NTB z评分的2年预测平均变化值为0.20(SE 0.02, SD 0.51),对照组为0.16(0.01, 0.51)。每年组间NTB总分变化为0.22(95% CI 0.002–0.042, p=0.030)。共有153人(12 %)退出了试验。干预组46人(7 %),对照组6人(1 %)出现了副反应,最常见的副反应为肌与骨骼疼痛,干预组32例(5 %),对照组无。

从这项大型的、长期的随机对照试验结果中可以得出,从大样本量的人群来看,多途径干预措施能够有效促进或维持高风险老年人的认知功能。

临床注册号:NCT01041989。

原文出处:

Tiia Ngandu, Jenni Lehtisalo, Alina Solomon, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. 2015.3.3. The Lancet.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021491, encodeId=f53f202149189, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Jan 03 23:44:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828028, encodeId=763918280280d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 29 04:44:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21766, encodeId=98a921e6629, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 13:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18494, encodeId=ed84184949d, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e351618312, createdName=sunqiuqiu, createdTime=Thu Mar 19 00:25:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18361, encodeId=bcef18361d7, content=组间变化应为0.022, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0a92650, createdName=kanghua1987, createdTime=Sun Mar 15 20:23:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18326, encodeId=f48e183268e, content=将来还要研究各种方法的最佳组合, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 21:08:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18316, encodeId=0d6f183163c, content=研究时间还是有点短, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 20:40:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021491, encodeId=f53f202149189, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Jan 03 23:44:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828028, encodeId=763918280280d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 29 04:44:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21766, encodeId=98a921e6629, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 13:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18494, encodeId=ed84184949d, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e351618312, createdName=sunqiuqiu, createdTime=Thu Mar 19 00:25:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18361, encodeId=bcef18361d7, content=组间变化应为0.022, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0a92650, createdName=kanghua1987, createdTime=Sun Mar 15 20:23:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18326, encodeId=f48e183268e, content=将来还要研究各种方法的最佳组合, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 21:08:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18316, encodeId=0d6f183163c, content=研究时间还是有点短, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 20:40:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-10-29 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021491, encodeId=f53f202149189, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Jan 03 23:44:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828028, encodeId=763918280280d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 29 04:44:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21766, encodeId=98a921e6629, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 13:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18494, encodeId=ed84184949d, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e351618312, createdName=sunqiuqiu, createdTime=Thu Mar 19 00:25:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18361, encodeId=bcef18361d7, content=组间变化应为0.022, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0a92650, createdName=kanghua1987, createdTime=Sun Mar 15 20:23:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18326, encodeId=f48e183268e, content=将来还要研究各种方法的最佳组合, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 21:08:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18316, encodeId=0d6f183163c, content=研究时间还是有点短, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 20:40:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-04-23 yuena

    有意义

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2021491, encodeId=f53f202149189, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Jan 03 23:44:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828028, encodeId=763918280280d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 29 04:44:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21766, encodeId=98a921e6629, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 13:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18494, encodeId=ed84184949d, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e351618312, createdName=sunqiuqiu, createdTime=Thu Mar 19 00:25:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18361, encodeId=bcef18361d7, content=组间变化应为0.022, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0a92650, createdName=kanghua1987, createdTime=Sun Mar 15 20:23:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18326, encodeId=f48e183268e, content=将来还要研究各种方法的最佳组合, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 21:08:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18316, encodeId=0d6f183163c, content=研究时间还是有点短, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 20:40:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-03-19 sunqiuqiu

    好文

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2021491, encodeId=f53f202149189, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Jan 03 23:44:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828028, encodeId=763918280280d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 29 04:44:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21766, encodeId=98a921e6629, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 13:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18494, encodeId=ed84184949d, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e351618312, createdName=sunqiuqiu, createdTime=Thu Mar 19 00:25:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18361, encodeId=bcef18361d7, content=组间变化应为0.022, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0a92650, createdName=kanghua1987, createdTime=Sun Mar 15 20:23:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18326, encodeId=f48e183268e, content=将来还要研究各种方法的最佳组合, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 21:08:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18316, encodeId=0d6f183163c, content=研究时间还是有点短, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 20:40:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-03-15 kanghua1987

    组间变化应为0.022

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2021491, encodeId=f53f202149189, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Jan 03 23:44:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828028, encodeId=763918280280d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 29 04:44:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21766, encodeId=98a921e6629, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 13:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18494, encodeId=ed84184949d, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e351618312, createdName=sunqiuqiu, createdTime=Thu Mar 19 00:25:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18361, encodeId=bcef18361d7, content=组间变化应为0.022, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0a92650, createdName=kanghua1987, createdTime=Sun Mar 15 20:23:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18326, encodeId=f48e183268e, content=将来还要研究各种方法的最佳组合, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 21:08:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18316, encodeId=0d6f183163c, content=研究时间还是有点短, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 20:40:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-03-14 medcardio

    将来还要研究各种方法的最佳组合

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2021491, encodeId=f53f202149189, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Jan 03 23:44:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828028, encodeId=763918280280d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 29 04:44:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21766, encodeId=98a921e6629, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 13:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18494, encodeId=ed84184949d, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e351618312, createdName=sunqiuqiu, createdTime=Thu Mar 19 00:25:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18361, encodeId=bcef18361d7, content=组间变化应为0.022, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0a92650, createdName=kanghua1987, createdTime=Sun Mar 15 20:23:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18326, encodeId=f48e183268e, content=将来还要研究各种方法的最佳组合, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 21:08:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18316, encodeId=0d6f183163c, content=研究时间还是有点短, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Mar 14 20:40:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-03-14 medcardio

    研究时间还是有点短

    0

相关资讯

Neuron:遗传性老年痴呆症背后的分子机制

一项来自马萨诸塞州综合医院和布莱根妇女医院的最新研究首次发现导致遗传性阿尔茨海默病发生的遗传突变是如何导致该疾病的破坏性影响的。这项研究成果在线发表在著名国际期刊neuron上,颠覆了之前关于早老素(presenilin)基因突变导致阿尔茨海默病破坏性作用的传统观念,并为针对阻断早老素活性而设计的药物无法有效治疗阿尔茨海默病提供了一种合理解释。   在之前的研究中,对presenil

Ann Clin Transl Neurol:老年痴呆,皮肤测试早诊断

根据公布在第67届美国神经病学会的一项研究:科学家发现皮肤测试可能有助更早揭示阿尔茨海默氏症和帕金森氏病。新研究表明,皮肤活检可用于检测这两种疾病中某些异常蛋白水平的升高。   研究报告的作者Ildefonso Rodriguez-Leyva,MD表示:到现在为止,没有脑活检的话,病理证实疾病是不可能的,所以这些疾病经常得不到诊断,直到病情进展。研究假设在胚胎时,皮肤与脑组织一

FDA批准阿特维斯Namzaric治疗阿尔茨海默氏型老年痴呆

全球仿制药巨头阿特维斯(Actavis)与合作伙伴Adamas制药公司近日宣布,复方新药Namzaric已获FDA批准用于正接受盐酸美金刚和盐酸多奈哌齐治疗且病情稳定的中度至重度阿尔茨海默氏型老年性痴呆(Alzheimer's type dementia)的治疗。阿特维斯计划于2015年将Namzaric推向市场。 Namzaric是一种每日一次的口服胶囊,由固定剂量美金刚和多奈哌齐(meman

Cell Reports :模拟平滑肌细胞 有助理解老年痴呆

项新的科学研究显示,科学家可以培养成长出与脑动脉中平滑肌肉细胞非常相似的细胞,这就将使其更容易研究血管疾病对神经退行性疾病的贡献。 平滑肌细胞是血管壁的一个重要组成部分,但出人意料的是,它们是器官特异性:例如脑动脉平滑肌细胞不同于冠状动脉的平滑肌细胞。这些细胞的详细属性在疾病过程中很重要的。因此,在实验室中研究疾病如阿尔茨海默氏病(AD)或血管性痴呆所使用的细胞需要紧密匹配活脑中的细胞。 分子

PNAS:施一公发现老年性痴呆潜在治疗药物

来自清华大学的研究人员证实,古细菌presenilin同系物PSH能够像人类γ-secretase一样裂解淀粉样前体蛋白(APP)。这一研究发现有可能会推动发现γ-secretase的抑制剂及调节剂。相关论文发表在3月2日的《美国国家科学院院刊》(PNAS)上。 清华大学的施一公(Yigong Shi)教授是这篇论文的通讯作者。施一公研究组主要致力于运用结构生物学和生物化学的

Brain:Duang!年轻人也会患老年痴呆!

近日,刊登在国际著名杂志Brain上的一篇研究论文中,来自美国西北大学的研究人员通过研究首次在20岁的年轻人大脑中的神经元中发现了淀粉样蛋白的积累,淀粉样蛋白是一种积累在大脑中的异常蛋白,其也是阿尔兹海默氏症发病的主要标志。 研究者认为,这项研究首次揭示了在年轻人的大脑中也会存在淀粉样蛋白的积累,而科学界长期以来一直认为这种蛋白仅会在老年人或阿尔兹海默氏症患者大脑神经元的外部进行积累;研究者Cha